Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia
Identifieur interne : 007575 ( Main/Exploration ); précédent : 007574; suivant : 007576Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia
Auteurs : Tadeusz Robak [Pologne, France, Espagne, Australie, Russie, Canada, Danemark, Italie, Nouvelle-Zélande, Hongrie, Suisse, États-Unis] ; Anna Dmoszynska ; Philippe Solal-Celigny ; Krzysztof Warzocha ; Javier Loscertales ; John Catalano ; Boris V. Afanasiev ; Loree Larratt ; Christian H. Geisler ; Marco Montillo ; Ilya Zyuzgin ; Peter S. Ganly ; Caroline Dartigeas ; András Rosta ; Jörg Maurer ; Myriam Mendila ; M. Wayne Saville ; Nancy Valente ; Michael K. Wenger ; Sergey I. MoiseevSource :
- Journal of clinical oncology [ 0732-183X ] ; 2010.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Purpose Rituximab, a monoclonal antibody that targets the CD20 cell surface antigen, has clinical activity in patients with non-Hodgkin's lymphoma and other B-lymphocyte disorders when administered alone or in combination with chemotherapy. Promising results have previously been reported in nonrandomized studies in patients with chronic lymphocytic leukemia (CLL). This trial was designed to compare chemoimmunotherapy with chemotherapy alone in patients with previously treated CLL. Patients and Methods This international, multicenter, randomized trial compared six cycles of rituximab plus fludarabine and cyclophosphamide (R-FC) with six cycles of fludarabine and cyclophosphamide alone (FC) in patients with previously treated CLL. A total of 552 patients with Binet stage A (10%), B (59%), or C (31 %) disease entered the study and were randomly assigned to receive R-FC (n = 276) or FC (n = 276). Results After a median follow-up time of 25 months, rituximab significantly improved progression-free survival in patients with previously treated CLL (hazard ratio = 0.65; P < .001; median, 30.6 months for R-FC v 20.6 months for FC). Event-free survival, response rate, complete response rate, duration of response, and time to new CLL treatment or death were also significantly improved. Although the rates of adverse events, grade 3 or 4 events, and serious adverse events were slightly higher in the R-FC arm, R-FC was generally well tolerated, with no new safety findings and no detrimental effect on quality of life. Conclusion R-FC significantly improved the outcome of patients with previously treated CLL.
Affiliations:
- Australie, Canada, Danemark, Espagne, France, Hongrie, Italie, Nouvelle-Zélande, Pologne, Russie, Suisse, États-Unis
- Centre-Val de Loire, Communauté de Madrid, Hongrie centrale, Hovedstaden, Pays de la Loire, Région Centre
- Budapest, Copenhague, Le Mans, Madrid, Tours
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 002725
- to stream PascalFrancis, to step Curation: 003861
- to stream PascalFrancis, to step Checkpoint: 002070
- to stream Main, to step Merge: 007B38
- to stream Main, to step Curation: 007575
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia</title><author><name sortKey="Robak, Tadeusz" sort="Robak, Tadeusz" uniqKey="Robak T" first="Tadeusz" last="Robak">Tadeusz Robak</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Hematology, Medical University</s1><s2>Lodz</s2><s3>POL</s3></inist:fA14><country>Pologne</country><wicri:noRegion>Lodz</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Hemato-Oncology and Bone Marrow Transplantation, Medical University</s1><s2>Lublin</s2><s3>POL</s3></inist:fA14><country>Pologne</country><wicri:noRegion>Lublin</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Hematology, Institute of Hematology and Transfusion Medicine</s1><s2>Warsaw</s2><s3>POL</s3></inist:fA14><country>Pologne</country><wicri:noRegion>Warsaw</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Department of Hematology, Clinique Victor Hugo</s1><s2>Le Mans</s2><s3>FRA</s3></inist:fA14><country>France</country><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Le Mans</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Department of Hematology, Centre Hospitalier Universitaire Bretonneau</s1><s2>Tours</s2><s3>FRA</s3></inist:fA14><country>France</country><placeName><region type="region">Centre-Val de Loire</region><region type="old region">Région Centre</region><settlement type="city">Tours</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Department of Hematology, Hospital Universitario de la Princesa</s1><s2>Madrid</s2><s3>ESP</s3></inist:fA14><country>Espagne</country><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Haematology Department and Dorevitch Pathology, Frankston Hospital</s1><s2>Frankston, Victoria</s2><s3>AUS</s3></inist:fA14><country>Australie</country><wicri:noRegion>Frankston, Victoria</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Bone Marrow Transplantation Centre and Department of Hematology, St Petersburg Pavlov State Medical University; Leningrad Regional Clinical Hospital</s1><s2>St Petersburg</s2><s3>RUS</s3></inist:fA14><country>Russie</country><wicri:noRegion>St Petersburg</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Department of Hematology, Walter C. Mackenzie Health Sciences Centre</s1><s2>Edmonton, Alberta</s2><s3>CAN</s3></inist:fA14><country>Canada</country><wicri:noRegion>Edmonton, Alberta</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Department of Hematology, Rigshospitalet</s1><s2>Copenhagen</s2><s3>DNK</s3></inist:fA14><country>Danemark</country><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Divisione Ematologia, Ospedale Niguarda</s1><s2>Milano</s2><s3>ITA</s3></inist:fA14><country>Italie</country><wicri:noRegion>Milano</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Department of Haematology, Christchurch Hospital</s1><s2>Christchurch</s2><s3>NZL</s3></inist:fA14><country>Nouvelle-Zélande</country><wicri:noRegion>Christchurch</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="13"><s1>Department of Medicine, National Institute of Oncology</s1><s2>Budapest</s2><s3>HUN</s3></inist:fA14><country>Hongrie</country><placeName><settlement type="city">Budapest</settlement><region nuts="2">Hongrie centrale</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Pharmaceuticals Division, F. Hoffmann-La Roche</s1><s2>Basel</s2><s3>CHE</s3></inist:fA14><country>Suisse</country><wicri:noRegion>Basel</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="15"><s1>Oncology Medical Research, Biogen Idec</s1><s2>Cambridge, MA</s2><s3>USA</s3></inist:fA14><country>États-Unis</country><wicri:noRegion>Cambridge, MA</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="16"><s1>Genentech</s1><s2>South San Francisco, CA</s2><s3>USA</s3></inist:fA14><country>États-Unis</country><wicri:noRegion>Genentech</wicri:noRegion></affiliation></author><author><name sortKey="Dmoszynska, Anna" sort="Dmoszynska, Anna" uniqKey="Dmoszynska A" first="Anna" last="Dmoszynska">Anna Dmoszynska</name></author><author><name sortKey="Solal Celigny, Philippe" sort="Solal Celigny, Philippe" uniqKey="Solal Celigny P" first="Philippe" last="Solal-Celigny">Philippe Solal-Celigny</name></author><author><name sortKey="Warzocha, Krzysztof" sort="Warzocha, Krzysztof" uniqKey="Warzocha K" first="Krzysztof" last="Warzocha">Krzysztof Warzocha</name></author><author><name sortKey="Loscertales, Javier" sort="Loscertales, Javier" uniqKey="Loscertales J" first="Javier" last="Loscertales">Javier Loscertales</name></author><author><name sortKey="Catalano, John" sort="Catalano, John" uniqKey="Catalano J" first="John" last="Catalano">John Catalano</name></author><author><name sortKey="Afanasiev, Boris V" sort="Afanasiev, Boris V" uniqKey="Afanasiev B" first="Boris V." last="Afanasiev">Boris V. Afanasiev</name></author><author><name sortKey="Larratt, Loree" sort="Larratt, Loree" uniqKey="Larratt L" first="Loree" last="Larratt">Loree Larratt</name></author><author><name sortKey="Geisler, Christian H" sort="Geisler, Christian H" uniqKey="Geisler C" first="Christian H." last="Geisler">Christian H. Geisler</name></author><author><name sortKey="Montillo, Marco" sort="Montillo, Marco" uniqKey="Montillo M" first="Marco" last="Montillo">Marco Montillo</name></author><author><name sortKey="Zyuzgin, Ilya" sort="Zyuzgin, Ilya" uniqKey="Zyuzgin I" first="Ilya" last="Zyuzgin">Ilya Zyuzgin</name></author><author><name sortKey="Ganly, Peter S" sort="Ganly, Peter S" uniqKey="Ganly P" first="Peter S." last="Ganly">Peter S. Ganly</name></author><author><name sortKey="Dartigeas, Caroline" sort="Dartigeas, Caroline" uniqKey="Dartigeas C" first="Caroline" last="Dartigeas">Caroline Dartigeas</name></author><author><name sortKey="Rosta, Andras" sort="Rosta, Andras" uniqKey="Rosta A" first="András" last="Rosta">András Rosta</name></author><author><name sortKey="Maurer, Jorg" sort="Maurer, Jorg" uniqKey="Maurer J" first="Jörg" last="Maurer">Jörg Maurer</name></author><author><name sortKey="Mendila, Myriam" sort="Mendila, Myriam" uniqKey="Mendila M" first="Myriam" last="Mendila">Myriam Mendila</name></author><author><name sortKey="Saville, M Wayne" sort="Saville, M Wayne" uniqKey="Saville M" first="M. Wayne" last="Saville">M. Wayne Saville</name></author><author><name sortKey="Valente, Nancy" sort="Valente, Nancy" uniqKey="Valente N" first="Nancy" last="Valente">Nancy Valente</name></author><author><name sortKey="Wenger, Michael K" sort="Wenger, Michael K" uniqKey="Wenger M" first="Michael K." last="Wenger">Michael K. Wenger</name></author><author><name sortKey="Moiseev, Sergey I" sort="Moiseev, Sergey I" uniqKey="Moiseev S" first="Sergey I." last="Moiseev">Sergey I. Moiseev</name></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">10-0212123</idno><date when="2010">2010</date><idno type="stanalyst">PASCAL 10-0212123 INIST</idno><idno type="RBID">Pascal:10-0212123</idno><idno type="wicri:Area/PascalFrancis/Corpus">002725</idno><idno type="wicri:Area/PascalFrancis/Curation">003861</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002070</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">002070</idno><idno type="wicri:doubleKey">0732-183X:2010:Robak T:rituximab:plus:fludarabine</idno><idno type="wicri:Area/Main/Merge">007B38</idno><idno type="wicri:Area/Main/Curation">007575</idno><idno type="wicri:Area/Main/Exploration">007575</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia</title><author><name sortKey="Robak, Tadeusz" sort="Robak, Tadeusz" uniqKey="Robak T" first="Tadeusz" last="Robak">Tadeusz Robak</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Hematology, Medical University</s1><s2>Lodz</s2><s3>POL</s3></inist:fA14><country>Pologne</country><wicri:noRegion>Lodz</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Hemato-Oncology and Bone Marrow Transplantation, Medical University</s1><s2>Lublin</s2><s3>POL</s3></inist:fA14><country>Pologne</country><wicri:noRegion>Lublin</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Hematology, Institute of Hematology and Transfusion Medicine</s1><s2>Warsaw</s2><s3>POL</s3></inist:fA14><country>Pologne</country><wicri:noRegion>Warsaw</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Department of Hematology, Clinique Victor Hugo</s1><s2>Le Mans</s2><s3>FRA</s3></inist:fA14><country>France</country><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Le Mans</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Department of Hematology, Centre Hospitalier Universitaire Bretonneau</s1><s2>Tours</s2><s3>FRA</s3></inist:fA14><country>France</country><placeName><region type="region">Centre-Val de Loire</region><region type="old region">Région Centre</region><settlement type="city">Tours</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Department of Hematology, Hospital Universitario de la Princesa</s1><s2>Madrid</s2><s3>ESP</s3></inist:fA14><country>Espagne</country><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Haematology Department and Dorevitch Pathology, Frankston Hospital</s1><s2>Frankston, Victoria</s2><s3>AUS</s3></inist:fA14><country>Australie</country><wicri:noRegion>Frankston, Victoria</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Bone Marrow Transplantation Centre and Department of Hematology, St Petersburg Pavlov State Medical University; Leningrad Regional Clinical Hospital</s1><s2>St Petersburg</s2><s3>RUS</s3></inist:fA14><country>Russie</country><wicri:noRegion>St Petersburg</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Department of Hematology, Walter C. Mackenzie Health Sciences Centre</s1><s2>Edmonton, Alberta</s2><s3>CAN</s3></inist:fA14><country>Canada</country><wicri:noRegion>Edmonton, Alberta</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Department of Hematology, Rigshospitalet</s1><s2>Copenhagen</s2><s3>DNK</s3></inist:fA14><country>Danemark</country><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Divisione Ematologia, Ospedale Niguarda</s1><s2>Milano</s2><s3>ITA</s3></inist:fA14><country>Italie</country><wicri:noRegion>Milano</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Department of Haematology, Christchurch Hospital</s1><s2>Christchurch</s2><s3>NZL</s3></inist:fA14><country>Nouvelle-Zélande</country><wicri:noRegion>Christchurch</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="13"><s1>Department of Medicine, National Institute of Oncology</s1><s2>Budapest</s2><s3>HUN</s3></inist:fA14><country>Hongrie</country><placeName><settlement type="city">Budapest</settlement><region nuts="2">Hongrie centrale</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Pharmaceuticals Division, F. Hoffmann-La Roche</s1><s2>Basel</s2><s3>CHE</s3></inist:fA14><country>Suisse</country><wicri:noRegion>Basel</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="15"><s1>Oncology Medical Research, Biogen Idec</s1><s2>Cambridge, MA</s2><s3>USA</s3></inist:fA14><country>États-Unis</country><wicri:noRegion>Cambridge, MA</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="16"><s1>Genentech</s1><s2>South San Francisco, CA</s2><s3>USA</s3></inist:fA14><country>États-Unis</country><wicri:noRegion>Genentech</wicri:noRegion></affiliation></author><author><name sortKey="Dmoszynska, Anna" sort="Dmoszynska, Anna" uniqKey="Dmoszynska A" first="Anna" last="Dmoszynska">Anna Dmoszynska</name></author><author><name sortKey="Solal Celigny, Philippe" sort="Solal Celigny, Philippe" uniqKey="Solal Celigny P" first="Philippe" last="Solal-Celigny">Philippe Solal-Celigny</name></author><author><name sortKey="Warzocha, Krzysztof" sort="Warzocha, Krzysztof" uniqKey="Warzocha K" first="Krzysztof" last="Warzocha">Krzysztof Warzocha</name></author><author><name sortKey="Loscertales, Javier" sort="Loscertales, Javier" uniqKey="Loscertales J" first="Javier" last="Loscertales">Javier Loscertales</name></author><author><name sortKey="Catalano, John" sort="Catalano, John" uniqKey="Catalano J" first="John" last="Catalano">John Catalano</name></author><author><name sortKey="Afanasiev, Boris V" sort="Afanasiev, Boris V" uniqKey="Afanasiev B" first="Boris V." last="Afanasiev">Boris V. Afanasiev</name></author><author><name sortKey="Larratt, Loree" sort="Larratt, Loree" uniqKey="Larratt L" first="Loree" last="Larratt">Loree Larratt</name></author><author><name sortKey="Geisler, Christian H" sort="Geisler, Christian H" uniqKey="Geisler C" first="Christian H." last="Geisler">Christian H. Geisler</name></author><author><name sortKey="Montillo, Marco" sort="Montillo, Marco" uniqKey="Montillo M" first="Marco" last="Montillo">Marco Montillo</name></author><author><name sortKey="Zyuzgin, Ilya" sort="Zyuzgin, Ilya" uniqKey="Zyuzgin I" first="Ilya" last="Zyuzgin">Ilya Zyuzgin</name></author><author><name sortKey="Ganly, Peter S" sort="Ganly, Peter S" uniqKey="Ganly P" first="Peter S." last="Ganly">Peter S. Ganly</name></author><author><name sortKey="Dartigeas, Caroline" sort="Dartigeas, Caroline" uniqKey="Dartigeas C" first="Caroline" last="Dartigeas">Caroline Dartigeas</name></author><author><name sortKey="Rosta, Andras" sort="Rosta, Andras" uniqKey="Rosta A" first="András" last="Rosta">András Rosta</name></author><author><name sortKey="Maurer, Jorg" sort="Maurer, Jorg" uniqKey="Maurer J" first="Jörg" last="Maurer">Jörg Maurer</name></author><author><name sortKey="Mendila, Myriam" sort="Mendila, Myriam" uniqKey="Mendila M" first="Myriam" last="Mendila">Myriam Mendila</name></author><author><name sortKey="Saville, M Wayne" sort="Saville, M Wayne" uniqKey="Saville M" first="M. Wayne" last="Saville">M. Wayne Saville</name></author><author><name sortKey="Valente, Nancy" sort="Valente, Nancy" uniqKey="Valente N" first="Nancy" last="Valente">Nancy Valente</name></author><author><name sortKey="Wenger, Michael K" sort="Wenger, Michael K" uniqKey="Wenger M" first="Michael K." last="Wenger">Michael K. Wenger</name></author><author><name sortKey="Moiseev, Sergey I" sort="Moiseev, Sergey I" uniqKey="Moiseev S" first="Sergey I." last="Moiseev">Sergey I. Moiseev</name></author></analytic><series><title level="j" type="main">Journal of clinical oncology</title><title level="j" type="abbreviated">J. clin. oncol.</title><idno type="ISSN">0732-183X</idno><imprint><date when="2010">2010</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Journal of clinical oncology</title><title level="j" type="abbreviated">J. clin. oncol.</title><idno type="ISSN">0732-183X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic agent</term><term>Cancerology</term><term>Chronic lymphocytic leukemia</term><term>Comparative study</term><term>Cyclophosphamide</term><term>Fludarabine</term><term>Immunotherapy</term><term>Progression free survival</term><term>Prolonged</term><term>Rituximab</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Rituximab</term><term>Prolongé</term><term>Etude comparative</term><term>Fludarabine</term><term>Traitement</term><term>Cancérologie</term><term>Immunothérapie</term><term>Cyclophosphamide</term><term>Leucémie lymphoïde chronique</term><term>Anticancéreux</term><term>Antigène CD20</term><term>Survie sans progression</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Purpose Rituximab, a monoclonal antibody that targets the CD20 cell surface antigen, has clinical activity in patients with non-Hodgkin's lymphoma and other B-lymphocyte disorders when administered alone or in combination with chemotherapy. Promising results have previously been reported in nonrandomized studies in patients with chronic lymphocytic leukemia (CLL). This trial was designed to compare chemoimmunotherapy with chemotherapy alone in patients with previously treated CLL. Patients and Methods This international, multicenter, randomized trial compared six cycles of rituximab plus fludarabine and cyclophosphamide (R-FC) with six cycles of fludarabine and cyclophosphamide alone (FC) in patients with previously treated CLL. A total of 552 patients with Binet stage A (10%), B (59%), or C (31 %) disease entered the study and were randomly assigned to receive R-FC (n = 276) or FC (n = 276). Results After a median follow-up time of 25 months, rituximab significantly improved progression-free survival in patients with previously treated CLL (hazard ratio = 0.65; P < .001; median, 30.6 months for R-FC v 20.6 months for FC). Event-free survival, response rate, complete response rate, duration of response, and time to new CLL treatment or death were also significantly improved. Although the rates of adverse events, grade 3 or 4 events, and serious adverse events were slightly higher in the R-FC arm, R-FC was generally well tolerated, with no new safety findings and no detrimental effect on quality of life. Conclusion R-FC significantly improved the outcome of patients with previously treated CLL.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Canada</li><li>Danemark</li><li>Espagne</li><li>France</li><li>Hongrie</li><li>Italie</li><li>Nouvelle-Zélande</li><li>Pologne</li><li>Russie</li><li>Suisse</li><li>États-Unis</li></country><region><li>Centre-Val de Loire</li><li>Communauté de Madrid</li><li>Hongrie centrale</li><li>Hovedstaden</li><li>Pays de la Loire</li><li>Région Centre</li></region><settlement><li>Budapest</li><li>Copenhague</li><li>Le Mans</li><li>Madrid</li><li>Tours</li></settlement></list><tree><noCountry><name sortKey="Afanasiev, Boris V" sort="Afanasiev, Boris V" uniqKey="Afanasiev B" first="Boris V." last="Afanasiev">Boris V. Afanasiev</name><name sortKey="Catalano, John" sort="Catalano, John" uniqKey="Catalano J" first="John" last="Catalano">John Catalano</name><name sortKey="Dartigeas, Caroline" sort="Dartigeas, Caroline" uniqKey="Dartigeas C" first="Caroline" last="Dartigeas">Caroline Dartigeas</name><name sortKey="Dmoszynska, Anna" sort="Dmoszynska, Anna" uniqKey="Dmoszynska A" first="Anna" last="Dmoszynska">Anna Dmoszynska</name><name sortKey="Ganly, Peter S" sort="Ganly, Peter S" uniqKey="Ganly P" first="Peter S." last="Ganly">Peter S. Ganly</name><name sortKey="Geisler, Christian H" sort="Geisler, Christian H" uniqKey="Geisler C" first="Christian H." last="Geisler">Christian H. Geisler</name><name sortKey="Larratt, Loree" sort="Larratt, Loree" uniqKey="Larratt L" first="Loree" last="Larratt">Loree Larratt</name><name sortKey="Loscertales, Javier" sort="Loscertales, Javier" uniqKey="Loscertales J" first="Javier" last="Loscertales">Javier Loscertales</name><name sortKey="Maurer, Jorg" sort="Maurer, Jorg" uniqKey="Maurer J" first="Jörg" last="Maurer">Jörg Maurer</name><name sortKey="Mendila, Myriam" sort="Mendila, Myriam" uniqKey="Mendila M" first="Myriam" last="Mendila">Myriam Mendila</name><name sortKey="Moiseev, Sergey I" sort="Moiseev, Sergey I" uniqKey="Moiseev S" first="Sergey I." last="Moiseev">Sergey I. Moiseev</name><name sortKey="Montillo, Marco" sort="Montillo, Marco" uniqKey="Montillo M" first="Marco" last="Montillo">Marco Montillo</name><name sortKey="Rosta, Andras" sort="Rosta, Andras" uniqKey="Rosta A" first="András" last="Rosta">András Rosta</name><name sortKey="Saville, M Wayne" sort="Saville, M Wayne" uniqKey="Saville M" first="M. Wayne" last="Saville">M. Wayne Saville</name><name sortKey="Solal Celigny, Philippe" sort="Solal Celigny, Philippe" uniqKey="Solal Celigny P" first="Philippe" last="Solal-Celigny">Philippe Solal-Celigny</name><name sortKey="Valente, Nancy" sort="Valente, Nancy" uniqKey="Valente N" first="Nancy" last="Valente">Nancy Valente</name><name sortKey="Warzocha, Krzysztof" sort="Warzocha, Krzysztof" uniqKey="Warzocha K" first="Krzysztof" last="Warzocha">Krzysztof Warzocha</name><name sortKey="Wenger, Michael K" sort="Wenger, Michael K" uniqKey="Wenger M" first="Michael K." last="Wenger">Michael K. Wenger</name><name sortKey="Zyuzgin, Ilya" sort="Zyuzgin, Ilya" uniqKey="Zyuzgin I" first="Ilya" last="Zyuzgin">Ilya Zyuzgin</name></noCountry><country name="Pologne"><noRegion><name sortKey="Robak, Tadeusz" sort="Robak, Tadeusz" uniqKey="Robak T" first="Tadeusz" last="Robak">Tadeusz Robak</name></noRegion><name sortKey="Robak, Tadeusz" sort="Robak, Tadeusz" uniqKey="Robak T" first="Tadeusz" last="Robak">Tadeusz Robak</name><name sortKey="Robak, Tadeusz" sort="Robak, Tadeusz" uniqKey="Robak T" first="Tadeusz" last="Robak">Tadeusz Robak</name></country><country name="France"><region name="Pays de la Loire"><name sortKey="Robak, Tadeusz" sort="Robak, Tadeusz" uniqKey="Robak T" first="Tadeusz" last="Robak">Tadeusz Robak</name></region><name sortKey="Robak, Tadeusz" sort="Robak, Tadeusz" uniqKey="Robak T" first="Tadeusz" last="Robak">Tadeusz Robak</name></country><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Robak, Tadeusz" sort="Robak, Tadeusz" uniqKey="Robak T" first="Tadeusz" last="Robak">Tadeusz Robak</name></region></country><country name="Australie"><noRegion><name sortKey="Robak, Tadeusz" sort="Robak, Tadeusz" uniqKey="Robak T" first="Tadeusz" last="Robak">Tadeusz Robak</name></noRegion></country><country name="Russie"><noRegion><name sortKey="Robak, Tadeusz" sort="Robak, Tadeusz" uniqKey="Robak T" first="Tadeusz" last="Robak">Tadeusz Robak</name></noRegion></country><country name="Canada"><noRegion><name sortKey="Robak, Tadeusz" sort="Robak, Tadeusz" uniqKey="Robak T" first="Tadeusz" last="Robak">Tadeusz Robak</name></noRegion></country><country name="Danemark"><region name="Hovedstaden"><name sortKey="Robak, Tadeusz" sort="Robak, Tadeusz" uniqKey="Robak T" first="Tadeusz" last="Robak">Tadeusz Robak</name></region></country><country name="Italie"><noRegion><name sortKey="Robak, Tadeusz" sort="Robak, Tadeusz" uniqKey="Robak T" first="Tadeusz" last="Robak">Tadeusz Robak</name></noRegion></country><country name="Nouvelle-Zélande"><noRegion><name sortKey="Robak, Tadeusz" sort="Robak, Tadeusz" uniqKey="Robak T" first="Tadeusz" last="Robak">Tadeusz Robak</name></noRegion></country><country name="Hongrie"><region name="Hongrie centrale"><name sortKey="Robak, Tadeusz" sort="Robak, Tadeusz" uniqKey="Robak T" first="Tadeusz" last="Robak">Tadeusz Robak</name></region></country><country name="Suisse"><noRegion><name sortKey="Robak, Tadeusz" sort="Robak, Tadeusz" uniqKey="Robak T" first="Tadeusz" last="Robak">Tadeusz Robak</name></noRegion></country><country name="États-Unis"><noRegion><name sortKey="Robak, Tadeusz" sort="Robak, Tadeusz" uniqKey="Robak T" first="Tadeusz" last="Robak">Tadeusz Robak</name></noRegion><name sortKey="Robak, Tadeusz" sort="Robak, Tadeusz" uniqKey="Robak T" first="Tadeusz" last="Robak">Tadeusz Robak</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 007575 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 007575 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:10-0212123
|texte= Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia
}}
| This area was generated with Dilib version V0.6.33. |  |